治疗肺动脉高压新药——WINREVAIR  

Pulmonary arterial hypertension treatment drugs——WINREVAIR

作　　者：宁宇杉[1] 孙韬华[2] 陈安进[2] 魏荣[3] NING Yu-han;SUN Tao-hua;CHEN An-jin;WEI Rong(Medical Journal Editorial Department,Qingdao Municipal Hospital,Qingdao 26601l,Shandong Province,China;Drug Clinical Trial Research Department,Qingdao Municipal Hospital,Qingdao 26601l,Shandong Province,China;Department of Pharmacy,Qingdao Municipal Hospital,Qingdao 26601l,Shandong Province,China)

机构地区：[1]青岛市市立医院医学杂志编辑部,山东青岛266011 [2]青岛市市立医院药物临床试验研究科,山东青岛266011 [3]青岛市市立医院药学部,山东青岛266011

出　　处：《中国临床药理学杂志》2025年第1期96-99,共4页The Chinese Journal of Clinical Pharmacology

基　　金：山东省医学会治疗药物监测科研基金资助项目(YXH2020ZX058)。

摘　　要：WINREVAIR的活性成分sotatercept-csrk是一种重组激活素受体IIA-Fc(ActRIIA-Fc)融合蛋白,可以通过改善促增殖(ActRIIA/Smad2/3介导)和抗增殖(BMPRII/Smad1/5/8介导)信号之间的平衡,从而调节血管增殖。2024年3月,WINREVAIR获美国食品和药品管理局批准,用于治疗成人肺动脉高压(PAH)。临床研究表明,WINREVAIR可提高运动能力,治疗导致全因死亡或PAH临床恶化事件的发生率降低84%。其常见药物不良反应包括头痛、鼻衄、皮疹等。The active ingredient of WINREVAIR,sotatercept-csrk,is a recombinant activin receptor IIA-Fc(ActRIIA-Fc)fusion protein that improves pro-proliferation(ActRIIA/Smad2/3-mediated)and anti-proliferation(BMPRII/Smad1/5/8-mediated)signals,thereby regulating vascular proliferation.In March 2024,WINREVAIRwas approved by the U.S.Food and Drug Administration for the treatment of pulmonary arterial hypertension(PAH)in adults.Clinical studies have shown that WINREVAIR can improve exercise capacityand reduce the incidence of all-cause death or clinical worsening of PAH by 84%.Common adverse drugreactions include headache,epistaxis,rash,etc.

关 键 词：WINREVAIR Sotatercept-csrk 重组激活素受体 融合蛋白 肺动脉高压 

分 类 号：R972[医药卫生—药品]